MAKENZIE GRIFFIN: Open Payments
NPI 1093209645 · PRINCE FREDERICK, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$406 in 22 payments from 15 companies in 2025. Trend: 2023 $965 · 2024 $1,267 · 2025 $406
Food & beverage: $406
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 3 | $52 |
| Novo Nordisk Inc | 3 | $49 |
| Astellas Pharma US Inc | 2 | $47 |
| Aimmune Therapeutics, Inc. | 2 | $35 |
| Lilly USA, LLC | 2 | $34 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Abbott Laboratories | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $22 |
| GlaxoSmithKline, LLC. | 1 | $20 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $19 |
Products named: Veozah, ZENPEP, VRAYLAR, GVOKE HYPOPEN, UBRELVY, PROCLAIM, INJECTAFER, KISUNLA.
Industry payments across MD — which companies pay providers there.
